IDDF2022-ABS-0073 HCC surveillance program in a nurse-led clinic: assessing adherence to guidelines and possibility of reducing pressure on services by applying AMAP score

M. Elnagar, M. Saleem, A. Beard, Samantha Whyld, A. Austin
{"title":"IDDF2022-ABS-0073 HCC surveillance program in a nurse-led clinic: assessing adherence to guidelines and possibility of reducing pressure on services by applying AMAP score","authors":"M. Elnagar, M. Saleem, A. Beard, Samantha Whyld, A. Austin","doi":"10.1136/gutjnl-2022-iddf.96","DOIUrl":null,"url":null,"abstract":"BackgroundNICE recommends offering 6 monthly surveillance with USS for all cirrhotic patients with an exception for patients identified for end-of-life care. But surveillance intervals are often missed when care is delivered through Consultant-led clinics. Having introduced a nurse-led stable cirrhosis clinic in 2016, we assessed whether the recommended interval was being achieved and what impact the ‘aMAP’ score stratifying annual HCC risk as low (<0.2%), medium (1%) and high (4%) might have on service utilisation.MethodsA retrospective review of all patients attending our nurse-led stable cirrhosis clinic. The review included demographic data, aetiology of liver disease, and calculation of aMAP (age, gender, albumin-bilirubin) scores using parameters from initial clinic visits. We assessed adherence to the twice-yearly US scan since our adaptation of NICE guidelines in 2018.ResultsBetween 2016–2018, 117 (49 female) cirrhotic patients were enrolled in the clinic. The majority of the patients had ALD (55) and NASH (24). Other aetiologies: HCV, HFE and PBC. All patients had Child A disease except 7 with Child B7–8. 13/117 patients were excluded from the surveillance because of other co-morbidities and age. Of the remaining, 90(87%) patients had their USS at 6 months interval, 2(2%) missed only one scan (not requested by clinician), 7(7%) failed to attend their appointments, 5(4%) either declined surveillance or were lost to follow up. aMAP score identified 70/104(67%) high risk, 29(28%) medium risk and only 5(5%) low risk for HCC. HCC was diagnosed in 4/104 patients after 3 years of follow-up (2 medium risks;2 high risks). Death was reported in 10 (1HCC;4 liver failure;3 other cancers;1 post-operative complication;1 sepsis). Despite interruptions caused by the COVID-19 pandemic, no HCC was diagnosed in 1st US scan after restarting the services.ConclusionsHCC surveillance organised through a dedicated nurse-led stable cirrhosis clinic can achieve excellent adherence to planned USS intervals. Only a small number were identified as low risk within our cohort using the aMAP score offering limited opportunity to reduce the volume of USS for this indication in Derby.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Clinical Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/gutjnl-2022-iddf.96","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundNICE recommends offering 6 monthly surveillance with USS for all cirrhotic patients with an exception for patients identified for end-of-life care. But surveillance intervals are often missed when care is delivered through Consultant-led clinics. Having introduced a nurse-led stable cirrhosis clinic in 2016, we assessed whether the recommended interval was being achieved and what impact the ‘aMAP’ score stratifying annual HCC risk as low (<0.2%), medium (1%) and high (4%) might have on service utilisation.MethodsA retrospective review of all patients attending our nurse-led stable cirrhosis clinic. The review included demographic data, aetiology of liver disease, and calculation of aMAP (age, gender, albumin-bilirubin) scores using parameters from initial clinic visits. We assessed adherence to the twice-yearly US scan since our adaptation of NICE guidelines in 2018.ResultsBetween 2016–2018, 117 (49 female) cirrhotic patients were enrolled in the clinic. The majority of the patients had ALD (55) and NASH (24). Other aetiologies: HCV, HFE and PBC. All patients had Child A disease except 7 with Child B7–8. 13/117 patients were excluded from the surveillance because of other co-morbidities and age. Of the remaining, 90(87%) patients had their USS at 6 months interval, 2(2%) missed only one scan (not requested by clinician), 7(7%) failed to attend their appointments, 5(4%) either declined surveillance or were lost to follow up. aMAP score identified 70/104(67%) high risk, 29(28%) medium risk and only 5(5%) low risk for HCC. HCC was diagnosed in 4/104 patients after 3 years of follow-up (2 medium risks;2 high risks). Death was reported in 10 (1HCC;4 liver failure;3 other cancers;1 post-operative complication;1 sepsis). Despite interruptions caused by the COVID-19 pandemic, no HCC was diagnosed in 1st US scan after restarting the services.ConclusionsHCC surveillance organised through a dedicated nurse-led stable cirrhosis clinic can achieve excellent adherence to planned USS intervals. Only a small number were identified as low risk within our cohort using the aMAP score offering limited opportunity to reduce the volume of USS for this indication in Derby.
IDDF2022-ABS-0073护士主导诊所的HCC监测项目:通过应用AMAP评分评估对指南的依从性和减少服务压力的可能性
nice建议对所有肝硬化患者提供6个月的USS监测,但确定需要临终关怀的患者除外。但是,当通过顾问领导的诊所提供护理时,往往会错过监测间隔。在2016年引入了一个由护士主导的稳定肝硬化诊所后,我们评估了是否达到了推荐的间隔时间,以及“aMAP”评分将年度HCC风险划分为低(<0.2%)、中(1%)和高(4%)可能对服务利用产生的影响。方法回顾性分析所有在我院护士主导的稳定肝硬化门诊就诊的患者。该综述包括人口统计数据、肝病病因学,以及使用首次门诊就诊参数计算aMAP(年龄、性别、白蛋白-胆红素)评分。我们评估了自2018年调整NICE指南以来每年两次的美国扫描的依从性。结果2016-2018年间,117例(49例女性)肝硬化患者入组临床。大多数患者患有ALD(55例)和NASH(24例)。其他病因:HCV, HFE和PBC。除7例患儿B7-8外,其余均为Child A。117例患者中有13例因其他合并症和年龄被排除在监测之外。其余90例(87%)患者间隔6个月进行超声扫描,2例(2%)患者仅错过一次扫描(未经临床医生要求),7例(7%)患者未能按时赴约,5例(4%)患者拒绝监测或失去随访。aMAP评分为70/104(67%)为高危,29(28%)为中危,只有5(5%)为低危。随访3年后,4/104例患者被诊断为HCC(2例中危,2例高危)。死亡10例(1例hcc;4例肝功能衰竭;3例其他癌症;1例术后并发症;1例败血症)。尽管COVID-19大流行造成了中断,但在重新启动服务后的第一次美国扫描中没有诊断出HCC。结论通过专门的护士领导的稳定肝硬化诊所组织的shcc监测可以很好地遵守计划的USS间隔。在我们的队列中,只有一小部分患者使用aMAP评分被确定为低风险,这为德比减少该适应症的USS数量提供了有限的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信